Theralink Technologies appoints Thomas Chilcott chief financial officer

Thursday October 1, 2020 0 comments Tags: Denver, Theralink Technologies, Thomas Chilcott, Mick Ruxin

DENVER -- Theralink Technologies (OTC: OBMP) announced the appointment of Thomas E. Chilcott, III CPA as chief financial officer effective Sept. 24.Theralink-logo 

Chilcott joins Theralink Technologies with more than 30 years of financial and operational experience in publicly traded and privately-owned companies.

Throughout his career, Chilcott has provided guidance on capital formation, M&A, restructurings, and creating shareholder value. From 2017 to 2019, he was chief financial officer, secretary and treasurer of Ampio Pharmaceuticals, Inc. (NYSE: AMPE), a biotechnology company primarily focused on the development of therapies to treat prevalent inflammatory conditions.

During his tenure at Ampio, he was instrumental in raising capital and leading the accounting and finance department including all SEC filings. Additionally, Chilcott, a CPA, was the president of Chilcott Consulting Group, where for more than 10 years he assisted many public and private biotechnology, healthcare and technology companies. 

"We are pleased to welcome Tom to the Theralink team during this critical inflection point in our company's history," said Mick Ruxin, Theralink Technologies president and CEO.

"Tom will not only add to our team extensive public company experience in healthcare, but also a deep understanding of 3rd party reimbursement, capital formation and leadership, which will be critical to the sustained growth of our company in the future.

“I look forward to working closely with Tom as we execute on our strategic goals, growth and delivering shareholder value."

"I look forward to complimenting the existing team at Theralink with my finance and operational experience,” said Chilcott.

“Theralink recently achieved a significant milestone of CLIA certification for its laboratory. We will immediately begin preparing to receive, test and bill for patient's breast cancer tumor specimens during the fourth quarter of this year."